"目录号: HY-13743
Roquinimex (Linomide; PNU212616; ABR212616)是免疫刺激剂，能增强NK细胞活性和巨噬细胞的细胞毒性，抑制血管生成和TNF α的分泌。
相关产品
Lenalidomide-Pomalidomide-TIC10-Necrostatin 2-Cot inhibitor-2-C 87-Mesaconitine-Sinensetin-Cot inhibitor-1-DCVC-Taurochenodeoxycholic acid-Bioymifi-Forsythoside B-Homoplantaginin-Hypaconitine-
生物活性
Description
Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.IC50 value:Target: TNF alphaProphylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3].
References
